A solid tumor diagnostics lead at a multinational pharmaceutical company discusses theiropinions around MRD and monitoring across different cancer indications, with their optimism forthese technologies focused on CRC. This stakeholder works at a company that conducts ctDNAtesting across thousands of patients in clinical trials every year, and is familiar with the MRDofferings from vendors such as Foundation Medicine, Natera, Guardant, Personalis,NeoGenomics, Invitae, Inivita, and Grail. This stakeholder dives deeply into the pain pointsaround sequencing tumors, outlines future trends around using WGS and methylationsequencing, and expresses a sentiment that the MRD/monitoring market will eventually bedominated by 1-2 key players.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.